Branislav Vajdic: Let me reiterate that AIMIGo is front and center of our development efforts and commercialization of that. As far as our IP is concerned, the good news is that we have incredibly deep IP portfolio here, including a watch, which I happen to believe is the ultimate solution here. You really don’t have to have any other device other than your watch to be able to do a 12-Lead ECG. But that’s not in the near-term focus. And perhaps that presents a partnership opportunity. Right? There are many players, well known players out there with a single lead ECG watch, and we have extremely well covered our intellectual property for the 12-Lead watch. So that’s not going to be on our immediate development list, but, again, partnership opportunities probably very significant.
Secondly, as far as patch is concerned, as I alluded to, we are very seriously considering the opportunities that it presents, well established markets, changing form factors, but technology wise, there is very little change that would be required between going from a credit card sized AIMIGo, HeartBeam AIMIGo device to a patch. So that is very much on our radar screen.
Unidentified Company Representative: And the next question asked, direct pay go-to-market is somewhat of a new direction. Can you shed some light on why this is potentially a superior strategy compared to RPM?
Robert Eno: I can take that one. Yeah, what we discussed is the refinement of the go-to-market strategy. And first, for those who don’t know, RPM, remote physiologic monitoring, are existing codes paid to physicians who prescribe devices to remotely monitored patients. What we’ve done is we’ve identified a number of market segments. RPM certainly could be one of them, but we’ve identified a number of additional market segments that we think are both big sized and also where there’s an entity that’s willing to pay for the solution outside of the reimbursement system. That’s what we’re describing as direct pay. And some of these require data that shows that we’re equivalent to a standard 12-Lead ECG, and we have those listed in the slide.
And then others that are more value based, we’ll be developing data on clinical and cost effectiveness. And the beauty of that is that we can start right away with the 12-Lead ECG, but then the data we gather for the value based usage is the same data that’s going to be useful for our efforts to establish a unique reimbursement code. So we think that these market segments we’ve identified have the potential to result in more value in a HeartBeam potentially than an RPM approach as well as being in alignment with this long term strategy of obtaining our own unique reimbursement code.
Unidentified Company Representative: And that concludes our webcast Q&A.
Operator: Thank you. And I would now like to turn the call back over to Dr. Vajdic for closing remarks.
Branislav Vajdic: Thank you, operator. I would like to thank each of you for joining our earnings conference call today and look forward to continuing to update you on our ongoing progress and growth. If we were unable to answer any of your questions, please reach out to our IR firm, MZ Group, who would be more than happy to assist. Thank you again, and all the best.
Operator: And this concludes today’s conference and you may disconnect your lines at this time. Thank you for your participation.
